2023-509188-26-00CompletedPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Feb 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- First submitted
- 27 May 2024
- Start date
- 27 Oct 2022
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Lupus (SLE)
- EU CT number
- 2023-509188-26-00
- EudraCT number
- 2021-001565-20
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 7
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy | Bydgoszcz | Poland | Completed |
| Uniwersytecki Szpital Kliniczny w Poznaniu | Poznan | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.